{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:00:47Z","timestamp":1790265647985,"version":"4.1.0"},"reference-count":28,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate healthcare resource utilization (HCRU) and costs for US commercially insured adult and pediatric patients with sickle cell disease (SCD) and matched non-SCD cohorts.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Patients with \u22653 SCD diagnosis codes (D57.0\u2013D57.219; D57.4\u2013D57.819) from July 2016 to December 2020 were identified from the IBM\n            <jats:sup>\u00ae<\/jats:sup>\n            MarketScan\n            <jats:sup>\u00ae<\/jats:sup>\n            Commercial database. The earliest SCD diagnosis was defined as the index date. Non-SCD control patients were matched 1:1 on age, gender and region. Continuous 6-month baseline and \u226512-month follow-up coverage was required. Follow-up HCRU and costs (2020 USD) were calculated per patient per year. Pediatric (&lt;18\u00a0years) and adult (\u226518\u00a0years) patients were analyzed separately.\n            <jats:bold>Results:<\/jats:bold>\n            For 1299 pediatric patients with SCD and matched controls, mean (SD) age was 10.0 (4.8) years and 51% were female; mean (SD) follow-up was 34.3 (14.4) months. In the first 12\u00a0months, pediatric patients with SCD had higher HCRU (hospitalizations: 0.6 vs 0.01; hospital length of stay: 2.4 vs 0.05\u00a0days; outpatient visits: 13.4 vs 6.0; office visits: 6.9 vs 4.7; prescriptions: 12.8 vs 3.8) and mean total costs ($31,445 vs $2844), mainly due to hospitalizations ($15,195 vs $477) and outpatient visits ($12,746 vs $1758), versus controls (all p\u00a0&lt;\u00a00.0001). For 2792 adults with SCD and matched controls, mean (SD) age was 38.0 (13.2) years and 62% were female; mean (SD) follow-up was 31.8 (13.7) months. Adults with SCD had higher per-patient per-year HCRU (hospitalizations: 0.8 vs 0.06; hospital length of stay: 4.3 vs 0.2\u00a0days; outpatient visits: 20.9 vs 9.3; office visits: 10.4 vs 6.9; prescriptions: 20.5 vs 11.7) and mean total costs ($42,550 vs $7522), also due to hospitalizations ($20,056 vs $1326) and outpatient visits ($17,508 vs $4301), versus controls (all p\u00a0&lt;\u00a00.0001).\n            <jats:bold>Conclusion:<\/jats:bold>\n            The economic burden of SCD among pediatric and adult patients is substantial with increased HCRU and costs compared with matched controls. Better treatments for SCD could reduce the economic burden for patients, as well as payers.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0006","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T11:21:01Z","timestamp":1743592861000},"source":"Crossref","is-referenced-by-count":2,"title":["Economic burden of sickle cell disease in the United States: a retrospective analysis of a commercial insurance database"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1756-1190","authenticated-orcid":false,"given":"Giovanna Tedesco","family":"Barcelos","sequence":"first","affiliation":[{"name":"Pfizer AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Telma","family":"Peixoto","sequence":"additional","affiliation":[{"name":"Pfizer Portugal, Porto Salvo, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Alvir","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6376-8469","authenticated-orcid":false,"given":"Jay","family":"Lin","sequence":"additional","affiliation":[{"name":"Novosys Health, Miami, FL 33145, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Baker","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle-cell disease in the United States: national and state estimates","volume":"85","author":"Brousseau DC","year":"2010","unstructured":"Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am. J. Hematol. 85(1), 77\u201378 (2010).","journal-title":"Am. J. Hematol."},{"issue":"12","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.15585\/mmwr.mm7312a1","article-title":"Birth prevalence of sickle cell disease and county-level social vulnerability \u2013 Sickle Cell Data Collection Program, 11 States, 2016\u20132020","volume":"73","author":"Kayle M","year":"2024","unstructured":"Kayle M, Blewer AL, Pan W Birth prevalence of sickle cell disease and county-level social vulnerability \u2013 Sickle Cell Data Collection Program, 11 States, 2016\u20132020. Morb. Mortal. Wkly Rep. 73(12), 248\u2013254 (2024).","journal-title":"Morb. Mortal. Wkly Rep."},{"issue":"2","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.semperi.2009.12.006","article-title":"History and current status of newborn screening for hemoglobinopathies","volume":"34","author":"Benson JM","year":"2010","unstructured":"Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin. Perinatol. 34(2), 134\u2013144 (2010).","journal-title":"Semin. Perinatol."},{"issue":"4","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell KL","year":"2010","unstructured":"Hassell KL. Population estimates of sickle cell disease in the U.S. Am. J. Prev. Med. 38(Suppl. 4), S512\u2013S521 (2010).","journal-title":"Am. J. Prev. Med."},{"issue":"2","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/03630269.2023.2211771","article-title":"Novel insights into the pathophysiology and treatment of sickle cell disease","volume":"47","author":"Araujo ADS","year":"2023","unstructured":"Araujo ADS, Silva Pinto AC, Lobo CLC Novel insights into the pathophysiology and treatment of sickle cell disease. Hemoglobin 47(2), 71\u201379 (2023).","journal-title":"Hemoglobin"},{"key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd P","year":"2019","unstructured":"Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev. Pathol. 14, 263\u2013292 (2019).","journal-title":"Annu Rev. Pathol."},{"issue":"11","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck D","year":"2019","unstructured":"Lubeck D, Agodoa I, Bhakta N Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw. Open 2(11), e1915374 (2019).","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.21408","article-title":"The cost of health care for children and adults with sickle cell disease","volume":"84","author":"Kauf TL","year":"2009","unstructured":"Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am. J. Hematol. 84(6), 323\u2013327 (2009).","journal-title":"Am. J. Hematol."},{"issue":"1","key":"e_1_3_9_11_2","article-title":"An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes","volume":"65","author":"Bou-Maroun LM","year":"2018","unstructured":"Bou-Maroun LM, Meta F, Hanba CJ, Campbell AD, Yanik GA. An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes. Pediatr. Blood Cancer 65(1), doi: 10.1002\/pbc.26758 (2018).","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","article-title":"Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance","volume":"7","author":"Johnson KM","year":"2023","unstructured":"Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 7(3), 365\u2013374 (2023).","journal-title":"Blood Adv."},{"issue":"4","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s41669-022-00330-w","article-title":"Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis","volume":"6","author":"Baldwin Z","year":"2022","unstructured":"Baldwin Z, Jiao B, Basu A Medical and non-medical costs of sickle cell disease and treatments from a US perspective: a systematic review and landscape analysis. Pharmacoecon. Open 6(4), 469\u2013481 (2022).","journal-title":"Pharmacoecon. Open"},{"issue":"4","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/pbc.22069","article-title":"Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States","volume":"53","author":"Mvundura M","year":"2009","unstructured":"Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr. Blood Cancer 53(4), 642\u2013646 (2009).","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1080\/13696998.2022.2133824","article-title":"Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis","volume":"25","author":"Gallagher ME","year":"2022","unstructured":"Gallagher ME, Chawla A, Brady BL, Badawy SM. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis. J. Med. Econ. 25(1), 1140\u20131148 (2022).","journal-title":"J. Med. Econ."},{"issue":"11","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","article-title":"Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers","volume":"23","author":"Shah NR","year":"2020","unstructured":"Shah NR, Bhor M, Latremouille-Viau D Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers. J. Med. Econ. 23(11), 1345\u20131355 (2020).","journal-title":"J. Med. Econ."},{"issue":"4","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.amepre.2010.01.004","article-title":"Sickle cell disease-related pediatric medical expenditures in the U.S","volume":"38","author":"Amendah DD","year":"2010","unstructured":"Amendah DD, Mvundura M, Kavanagh PL, Sprinz PG, Grosse SD. Sickle cell disease-related pediatric medical expenditures in the U.S. Am. J. Prev. Med. 38(Suppl. 4), S550\u2013S556 (2010).","journal-title":"Am. J. Prev. Med."},{"issue":"8","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s12325-023-02545-7","article-title":"Economic and clinical burden of managing sickle cell disease with recurrent vaso-occlusive crises in the United States","volume":"40","author":"Udeze C","year":"2023","unstructured":"Udeze C, Evans KA, Yang Y Economic and clinical burden of managing sickle cell disease with recurrent vaso-occlusive crises in the United States. Adv. Ther. 40(8), 3543\u20133558 (2023).","journal-title":"Adv. Ther."},{"issue":"10","key":"e_1_3_9_19_2","first-page":"965","article-title":"Incremental health care burden of bleeding among patients with venous thromboembolism in the United States","volume":"21","author":"Amin A","year":"2015","unstructured":"Amin A, Bruno A, Trocio J, Lin J, Lingohr-Smith M. Incremental health care burden of bleeding among patients with venous thromboembolism in the United States. J. Manag. Care Spec. Pharm. 21(10), 965\u2013972 (2015).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"11","key":"e_1_3_9_20_2","doi-asserted-by":"crossref","first-page":"e2344546","DOI":"10.1001\/jamanetworkopen.2023.44546","article-title":"Use of disease-modifying treatments in patients with sickle cell disease","volume":"6","author":"Newman TV","year":"2023","unstructured":"Newman TV, Yang J, Suh K, Jonassaint CR, Kane-Gill SL, Novelli EM. Use of disease-modifying treatments in patients with sickle cell disease. JAMA Netw. Open 6(11), e2344546 (2023).","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/bjh.19632","article-title":"A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: implications for understanding the mechanism of action and evaluating response to therapy","volume":"205","author":"Sadaf A","year":"2024","unstructured":"Sadaf A, Dong M, Pfeiffer A A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: implications for understanding the mechanism of action and evaluating response to therapy. Br. J. Haematol. 205(3), 1147\u20131158 (2024).","journal-title":"Br. J. Haematol."},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.01.084"},{"issue":"2","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005","volume":"128","author":"Lanzkron S","year":"2013","unstructured":"Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979\u20132005. Public Health Rep. 128(2), 110\u2013116 (2013).","journal-title":"Public Health Rep."},{"issue":"1","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.26765","article-title":"Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease","volume":"98","author":"Kang HA","year":"2023","unstructured":"Kang HA, Barner JC, Lawson KA, Rascati K, Mignacca RC. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease. Am. J. Hematol. 98(1), 90\u2013101 (2023).","journal-title":"Am. J. Hematol."},{"issue":"26","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","article-title":"Update on the use of hydroxyurea therapy in sickle cell disease","volume":"124","author":"Wong TE","year":"2014","unstructured":"Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood 124(26), 3850\u20133857; quiz 4004 (2014).","journal-title":"Blood"},{"issue":"1","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<26::AID-AJH5>3.0.CO;2-F","article-title":"Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"64","author":"Moore RD","year":"2000","unstructured":"Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Am. J. Hematol. 64(1), 26\u201331 (2000).","journal-title":"Am. J. Hematol."},{"issue":"3","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities","volume":"3","author":"Brandow AM","year":"2010","unstructured":"Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev. Hematol. 3(3), 255\u2013260 (2010).","journal-title":"Expert Rev. Hematol."},{"issue":"6","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review","volume":"134","author":"Lee L","year":"2019","unstructured":"Lee L, Smith-Whitley K, Banks S, Puckrein G. Reducing health care disparities in sickle cell disease: a review. Public Health Rep. 134(6), 599\u2013607 (2019).","journal-title":"Public Health Rep."},{"key":"e_1_3_9_29_2","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1457158","article-title":"Sickle cell disease: a comparative perspective on global and national initiatives","volume":"3","author":"Kumar A","year":"2024","unstructured":"Kumar A, Bhattacharya S. Sickle cell disease: a comparative perspective on global and national initiatives. Front. Hematol. 3, doi: 10.3389\/frhem.2024.1457158 (2024).","journal-title":"Front. Hematol."},{"issue":"8","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/pm\/pnab092","article-title":"Implementation of individualized pain care plans decreases length of stay and hospital admission rates for high utilizing adults with sickle cell disease","volume":"22","author":"Welch-Coltrane JL","year":"2021","unstructured":"Welch-Coltrane JL, Wachnik AA, Adams MCB Implementation of individualized pain care plans decreases length of stay and hospital admission rates for high utilizing adults with sickle cell disease. Pain Med. 22(8), 1743\u20131752 (2021).","journal-title":"Pain Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T08:47:06Z","timestamp":1744793226000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.57264\/cer-2025-0006"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0006","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"article-number":"e250006"}}